Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.
Eli Lilly reported that its experimental triple-agonist drug retatrutide helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial, with more than half of patients dropping below the obesity threshold.
Eli Lilly is stepping up legal action against a booming black market for retatrutide, an experimental weight-loss drug the company is counting on to expand its franchise beyond approved medications like Zepbound.
Eli Lilly announced positive results from two additional Phase 3 trials of its experimental obesity drug retatrutide (a 'triple-G' GLP-1 receptor agonist), showing it did not increase overall heart risk. The company plans to submit an FDA application in Q1 2027.
Eli Lilly is in advanced talks to acquire AtaiBeckley, a psychedelic medicine company, with a deal potentially announced this week. The acquisition underscores growing interest from major pharmaceutical companies in psychedelic therapies.
The FDA selected seven companies including Eli Lilly and Regeneron for a pilot program designed to speed up reviews of new domestic pharmaceutical manufacturing facilities, aiming to strengthen U.S. drug supply chains.
Eli Lilly provided its experimental 'triple-G' weight loss drug retatrutide to a 79-year-old patient through the FDA's compassionate use program, marking an extremely rare instance of pre-approval access to an obesity medication.
CVS Health announced it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option and begin coverage for the drugmaker's newly approved obesity pill, Forza.
Eli Lilly reported that a high dose of its gene-editing therapy from Verve Therapeutics reduced cholesterol levels by 62% in participants in an early-stage clinical trial, representing a significant advance in gene-editing treatments for cardiovascular disease.
New ethics disclosures reveal President Trump purchased stock in Eli Lilly and an injectable device manufacturer while his health agencies implemented policies benefiting these companies' obesity drug products.
France's medicines regulator has imposed fines on Novo Nordisk and Eli Lilly for their weight loss drug advertising campaigns, marking a significant regulatory action against the pharmaceutical giants' marketing practices.
Eli Lilly has entered a deal with AI startup Profluent to develop AI-designed enzymes capable of inserting entire genes, moving beyond traditional CRISPR technology. The partnership aims to reshape genetic medicine by using artificial intelligence to create novel gene editing tools.
